Christian Trautwein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Trautwein has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Michael P. Manns
Department of Gastroenterology, Hepatology and Endocrinology Medizinische Hochschule Hannover Carl-Neuberg-Strasse 1 D-30625 Hannover Germany
3 shared publicationsArnold Ganser
Haematology, Haemostasis and Oncology
1 shared publicationChristian Klein
Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
1 shared publication- Christian Liedtke
Department of Medicine III, Uniklinik RWTH Aachen, Aachen, Germany
1 shared publication Frank Tacke
Department of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, Hannover, Germany
1 shared publicationGregory J. Gores
Mayo Clinic College of Medicine, Rochester, MN
1 shared publication
Latest Publications
- 1 February 2006
- Published by Elsevier in Journal of Hepatology
- Vol. 44 (2) , 342-349
Interferon-α enhances TRAIL-mediated apoptosis by up-regulating caspase-8 transcription in human hepatoma cells
- 1 February 2006
- Published by Elsevier in Journal of Hepatology
- Vol. 44 (2) , 342-349
Interferon-α enhances TRAIL-mediated apoptosis by up-regulating caspase-8 transcription in human hepatoma cells
- 31 January 2006
- Published by Wiley in Liver International
- Vol. 26 (2) , 173-181
Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6‐year survival in patients with chronic liver disease
Abstract: Background/Aims: Alterations of plasma coagulation factor XIII may contribute to bleeding disorders in patients with liver cirrhosis. As standard clotting tests such as prothrombin time or activated thromboplastin time (aPTT) cannot detect factor XIII deficiency, this may often be overlooked in clinical practice. We aimed to define factor XIII's clinical and prognostic role in chronic liver disease.Patients and methods: Factor XIII activities were assessed among various other parameters in 111 patients with chronic liver diseases during evaluation for liver transplantation in a prospective study.Results: Unlike coagulation factors II, V or VII, factor XIII activity was maintained in the majority of patients with liver cirrhosis. However, although rarely, factor XIII deficiencies (Conclusions: Factor XIII deficiency is rare in patients with liver cirrhosis, but is associated with a clinical bleeding tendency and an unfavorable prognosis for future hemorrhages and survival.
- 31 January 2006
- Published by Wiley in Liver International
- Vol. 26 (2) , 173-181
Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6‐year survival in patients with chronic liver disease
Abstract: Background/Aims: Alterations of plasma coagulation factor XIII may contribute to bleeding disorders in patients with liver cirrhosis. As standard clotting tests such as prothrombin time or activated thromboplastin time (aPTT) cannot detect factor XIII deficiency, this may often be overlooked in clinical practice. We aimed to define factor XIII's clinical and prognostic role in chronic liver disease.Patients and methods: Factor XIII activities were assessed among various other parameters in 111 patients with chronic liver diseases during evaluation for liver transplantation in a prospective study.Results: Unlike coagulation factors II, V or VII, factor XIII activity was maintained in the majority of patients with liver cirrhosis. However, although rarely, factor XIII deficiencies (Conclusions: Factor XIII deficiency is rare in patients with liver cirrhosis, but is associated with a clinical bleeding tendency and an unfavorable prognosis for future hemorrhages and survival.
- Open Access
- 25 October 2005
- Published by Wolters Kluwer Health in Hepatology
- Vol. 42 (5) , 1082-1090
Lack of gp130 Expression Results in More Bacterial Infection and Higher Mortality During Chronic Cholestasis in Mice *
: Chronic cholestasis is associated with increased bacterial infections and sepsis resulting in higher mortality in humans. In the current study, we investigated the relevance of gp130-dependent pathways after bile duct ligation (BDL). BDL was performed in conditional gp130 knockout (loxP/Cre system) mice and respective controls. Liver injury, regulation of the acute phase response, and the impact on survival and bacterial infections were determined. Acute BDL resulted in increased IL-6 levels, Stat3 activation, and an increase in acute-phase proteins (serum-amyloid-A [SAA]), which was blocked in gp130-deleted animals. In addition, the antimicrobial gene hepcidin was regulated in a gp130-dependent manner after BDL. During chronic cholestasis Stat3 activation was dramatically reduced, while high SAA levels were maintained via gp130-dependent signaling. Inhibition of gp130-dependent pathways resulted in higher mortality and liver damage, which was associated with higher infiltration of immune-activated cells and increased germ number in the liver. In conclusion , during acute and chronic cholestasis, the gp130 system is essential for controlling the acute-phase response. Lack of gp130 expression results in pronounced bacterial growth in bile and liver after BDL, which is associated with higher mortality. Activation of gp130-dependent pathways after BDL is essential and appears to be a therapeutic target during cholestasis. (Hepatology 2005;42:1082–1090.)
- 25 October 2005
- Published by Wolters Kluwer Health in Hepatology
- Vol. 42 (5) , 1082-1090
Open AccessLack of gp130 Expression Results in More Bacterial Infection and Higher Mortality During Chronic Cholestasis in Mice *
: Chronic cholestasis is associated with increased bacterial infections and sepsis resulting in higher mortality in humans. In the current study, we investigated the relevance of gp130-dependent pathways after bile duct ligation (BDL). BDL was performed in conditional gp130 knockout (loxP/Cre system) mice and respective controls. Liver injury, regulation of the acute phase response, and the impact on survival and bacterial infections were determined. Acute BDL resulted in increased IL-6 levels, Stat3 activation, and an increase in acute-phase proteins (serum-amyloid-A [SAA]), which was blocked in gp130-deleted animals. In addition, the antimicrobial gene hepcidin was regulated in a gp130-dependent manner after BDL. During chronic cholestasis Stat3 activation was dramatically reduced, while high SAA levels were maintained via gp130-dependent signaling. Inhibition of gp130-dependent pathways resulted in higher mortality and liver damage, which was associated with higher infiltration of immune-activated cells and increased germ number in the liver. In conclusion , during acute and chronic cholestasis, the gp130 system is essential for controlling the acute-phase response. Lack of gp130 expression results in pronounced bacterial growth in bile and liver after BDL, which is associated with higher mortality. Activation of gp130-dependent pathways after BDL is essential and appears to be a therapeutic target during cholestasis. (Hepatology 2005;42:1082–1090.)